EPM sat with Marivi Mendizabal, vice president Quality and Regulatory, Cytiva, as she explains how government policy and regulatory trends impact the biopharma industry, and how collaborating with the government can enhance biopharma resilience.
Key insights:
- The accelerated approval process for the COVID-19 vaccines was about reducing unnecessary delays without compromising efficacy, safety and quality standards.
- Collaborating with the government would ensure faster regulatory decisions and access to drugs are possible without compromising safety.
- 63% of the respondents said that COVID-19 was a “wake-up call” for our governments to do more to support the industry.
In 2021, Cytiva launched the inaugural Biopharma Resilience Index, revealing how the biopharma industry is performing across in five key pillars: supply chain resilience, talent pool, R&D ecosystem, manufacturing agility, and government policy and regulation in 20 countries. This year, we dug deeper into one of those pillars—government policy and regulation. This survey of 500 senior biopharma executives worldwide reveals how greater government involvement in the industry during COVID-19 affected various areas of the industry.